CHICAGO—SourceOne Global Partners announced the peer-reviewed journal, Alternative Therapies in Health and Medicine, published the results of a double blind study comparing the bioavailability of patented CoQsource® to three other bio-enhanced coenzyme Q10 (CoQ10) formulations (March/April 2009; 15(2)). The study is entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System”.
According to Dr. Zheng-Xian Liu, lead author of the study and author of more than 60 other peer-reviewed published studies, the scientific and medical community has emphasized the importance in supplementing with CoQ10 and improving the uptake and bioavailability in CoQ10 formulations, especially with the dramatic increase in the number of people taking stain drugs.
In this study, the relative bioavailability of a single oral dose of 120 mg of CoQ10 was assessed using the area under curve (AUC (0-10h)) in which the value for CoQsource reached 30.62 µg/ml/10h; a 622-percent higher bioavailability than the oil-based formula and a 499-percent higher bioavailability than the solubilizate.
“These are the most compelling clinically proven absorption results of any CoQ10 formulation that have been published to date,” said Dr. Liu.
CoQsourc is a patented, lipid-based formulation that naturally self-assembles on contact with an aqueous phase into an association colloid delivery system known as VESIsorb®.
Developed by Vesifact, Baar, Switzerland, VESIsorb is protected worldwide by multiple U.S. and international granted and pending patents. Marc Weder, co-founder and CEO of Vesifact, commented: “These results highlight the many advantages that this delivery system represents. We have been able to broaden the applications for certain bio-active ingredients like CoQ10 into functional foods, drink mixes, beverages and cosmetic products. We have succeeded in this area by addressing issues such as water solubility, oxidative stability, shelf life and uniformity of dispersion in the delivery medium.”
Weder added that Vesifact’s newest research has focused on utilizing VESIsorb with omega-3 concentrated EPA/DHA (OmegaChoice™) alone and in combination with CoQsource; and utilizing VESIsorb with citrus flavonoids (PMF-source™) alone and in combination with palm tocotrienols (TocoSource®).
“It is clear that CoQsource is the most exceptional and exciting CoQ10 formulation available with regard to its pharmacokinetic profile,” said Jesse Lopez, CEO and Founder of SourceOne. “This study showed higher relative bioavailability not compared to CoQ10 powder, but compared to patented soft gel enhanced absorption delivery systems. The results speak for themselves.”
This technology allows SourceOne to offer bio-enhanced ingredients and proprietary formulas containing CoQ10 in either the ubiquinone or ubiquinol (QH) forms. Lopez added, “Perhaps even more compelling is our ability to deliver proprietary Omega-3 and CoQ10 combinations along with utilizing the VESIsorb delivery system to significantly improve the absorption of other natural lipophilic bio-actives such as vitamin D3, resveratrol, citrus polymethoxylated flavones (PMF), palm tocotrienols, and gamma-tocopherols.”
CoQsource is available worldwide exclusively from SourceOne in various potencies up to 200 mg. SourceOne can offer a 100-percent water-soluble form of CoQ10 and deliver the formulation in solid dosage forms, drink mixes, stick packs, food products, beverages